Phage Therapy Advances in Brazil: Universities Pioneer Fight Against Superbugs

Understanding Phage Therapy: A Natural Weapon Against Bacteria

Phage therapy, or fagoterapia in Portuguese, harnesses bacteriophages—viruses that specifically infect and destroy bacteria— as a targeted treatment for bacterial infections. Unlike broad-spectrum antibiotics, which can harm beneficial microbes and contribute to resistance, phages attack only the targeted pathogen, multiplying within it until the bacterium lyses, or bursts, releasing more phages to continue the cycle. This process is highly selective, minimizing side effects on human cells or the gut microbiome.

In Brazil, where antimicrobial resistance claims over 33,000 lives annually, phage therapy represents a promising alternative amid the global superbug crisis. Researchers at leading universities are at the forefront, developing phage banks and protocols to combat strains like KPC-producing Klebsiella pneumoniae, a notorious hospital-acquired superbug.

Brazil's Pioneering History in Phage Research

Brazil's engagement with phage therapy dates back to the 1920s, making it one of the early adopters worldwide. Physician José da Costa Cruz at the Instituto Oswaldo Cruz (Fiocruz) isolated phages and treated dysentery outbreaks, producing the first large-scale phage preparation, Bacteriofagina disenterica. This innovation was distributed nationally, showcasing Brazil's early translational research prowess.

The therapy declined in the 1940s with antibiotics' rise, but archives at USP and Fiocruz have revived interest. Today, universities like USP and Unifesp build on this legacy, integrating historical insights with modern genomics.

The Superbug Threat Driving Brazilian Innovation

Superbactérias, or superbugs, such as multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and KPC-Klebsiella pneumoniae, proliferate in Brazilian hospitals, complicating surgeries, transplants, and chemotherapy. The Ministry of Health reported over 33,000 AMR-related deaths in 2025, with projections of US$3.4 trillion global GDP loss by 2030.

Brazilian universities respond through networks like Cepid B3 (FAPESP-funded, R$42 million), uniting USP, Unicamp, Unesp, and Unifesp to characterize bacteria and phages. This higher education-led effort positions Brazil as a South American leader in phage research.

USP's Cepid B3: Building Brazil's Phage Arsenal

The Centro de Pesquisa em Biologia de Bactérias e Bacteriófagos (Cepid B3) at USP's Instituto de Química, led by Shaker Chuck Farah, is central to Brazil's phage revolution. With 160+ researchers, it maps ~300 phages, focusing on genomic safety and production. Postdoctoral researcher Ariosvaldo Pereira dos Santos Junior develops protocols for compassionate use, partnering with Hospital das Clínicas da FMUSP for clinical isolates.

Legacy builder Aline Maria da Silva advanced phage evolution techniques before her 2024 passing. Cepid B3's FagoLimp project tested hospital decontamination, reducing Klebsiella in one facility.Explore research positions at USP to contribute to such breakthroughs.

Unifesp's Leadership: The KIDNAP Study Protocol

At Universidade Federal de São Paulo (Unifesp), infectologist Ana Cristina Gales drives phage decolonization research. The KIDNAP Study Protocol, published in November 2025 in the International Journal of Antimicrobial Agents, targets intestinal KPC-Klebsiella in 15 high-risk patients at a São Paulo tertiary hospital. Personalized phage cocktails are administered for 14 days, assessing efficacy (>80% feasibility), safety, microbiome impact, and resistance mutants.

Authors Iris Najjar, Larissa Simão Gandolpho, and team aim to standardize phage therapy in resource-limited settings. Ethics-approved, it paves the way for Phase trials.Read the KIDNAP protocol.

Photo by Lucas Vasques on Unsplash

Compassionate Use Cases: Real-World Success in Brazil

Despite regulations limiting to compassionate use, successes emerge. Infectologist Roberto Badaró at Senai Cimatec treated a patient with resistant Acinetobacter and Pseudomonas threatening amputation. Intravenous and topical phages over 30 days healed the wound, saving the limb—now slated for publication.

• Pharma Julio Cezar Franco (Unifesp Diadema) isolated 62 new phages in 2025 from rivers, compost, and clinical sources.
• Danielle Murici Brasiliense (Instituto Evandro Chagas) builds Amazon phage bank for regional strains.

Global benchmarks: Belgium's 77.2% clinical improvement in 100 cases; Uruguay's Kinzbio >90% cure in 20+ cases.

Regulatory Hurdles and Pathways Forward

Anvisa's stance—phages as manipulable biologicals yet requiring full trials—stalls progress. Agriculture allows phages (e.g., mastitis), but human use awaits GMP platforms. Unifesp and USP push ethics protocols; São Paulo eyes a statewide phage bank with Butantan Institute.

Challenges include production scalability, transport (e.g., Amazon), and resistance evolution. Solutions: AI phage design, prophylactic mucosal applications.

Global Context: Brazil's Emerging Role

WHO's 2025 report notes 1-in-6 resistant infections; Belgium, Georgia lead clinically. South America grows, Brazil topping publications (agri/food focus). Partnerships: USP-Oxford, Badaró-UCSD Ipath.

Future Outlook: Phage Banks and Clinical Trials

Brazilian universities target 2026 milestones: KIDNAP results, expanded trials, AI-optimized phages. Cepid B3 envisions rapid-response banks; prophylactic strategies could prevent outbreaks.

Higher ed drives this: Faculty roles in microbiology boom.

Careers in Phage Research: Opportunities in Brazilian Academia

USP, Unifesp seek microbiologists, bioinformaticians. University jobs in Brazil offer impact against AMR. Craft your academic CV for biotech roles.

Explore Rate My Professor for insights on mentors like Gales.

Photo by KOBU Agency on Unsplash

Conclusion: Brazil's Universities Spearheading a Phage Renaissance

Brazilian higher education, via USP's Cepid B3 and Unifesp's trials, positions the nation as a phage therapy leader. Overcoming regulations unlocks lives saved. For higher ed jobs, research positions, or career advice, visit AcademicJobs.com. Engage via comments below.